Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Christine Brefel-Courbon15
Treatment Outcome52
Christine Brefel-Courbon Sauf Treatment Outcome" 12
Treatment Outcome Sauf Christine Brefel-Courbon" 49
Christine Brefel-Courbon Et Treatment Outcome 3
Christine Brefel-Courbon Ou Treatment Outcome 64
Corpus679
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000339 Fabienne Ory-Magne [France] ; Christine Brefel-Courbon [France] ; Marion Simonetta-Moreau [France] ; Nelly Fabre [France] ; Jean Albert Lotterie [France] ; Patrick Chaynes [France] ; Isabelle Berry [France] ; Yves Lazorthes [France] ; Olivier Rascol [France]Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
000508 Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
000569 Rascol [France] ; Kasia Sieradzan [Royaume-Uni] ; Hélène Peyro-Saint-Paul [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Jean Michel Senard [France] ; Philippe Ladure [France] ; Jean Louis Montastruc [France] ; Andrew Lees (neurologue) [Royaume-Uni]Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024